Promising results of a clinical study of a medicament for the treatment of the K-19 registered a team of UMBAL "St Marina" - Pleven
Nelecares of University Hospital "St. Marina "- Pleven are involved in a large-scale international clinical study, which is located in Phase III, a new molecule that stops the replication of the SARS-COV-2 . What are the data so far and how the healing establishment became one of the centers of clinical trials, we chat with the Chief Explorer Dr. Ivan Mondanski, Ph.
- Dr Mondanski, information has come out that you are a team that makes an international clinical study of a medicine for the treatment of the K-19, but I would like to start from the beginning. How did you find yourself in this team?
- I have invited by the company that presents this study. I guess to my invitation has come thanks to the number of patients who have passed me that I have treated by Kovid. I believe that the profile of the hospital in which I work has been an important factor - it is innovative and high-tech. This is a great international study involving over 12 countries with 4-5 centers in each one, so it was the honor to invite me and the opportunity to participate in this study.
- Did you have fluctuations whether to accept?
"I first wished to get acquainted with the type of medication and, above all, with its side reactions, if any. But after I met here, I say that the study is in Phase III, I found that heavy or significant side effects had not been reported, and I was admitted to join it.
[Whole interview.] (Https://blsbg.com/en/download/file/page-section/22046)
Source: Quo vadis 
